Recombinant Human CTLA4 Protein (Fc Tag)

Introducing the Recombinant Human CTLA4 Protein (FC Tag), a cutting-edge product designed to revolutionize the field of immunotherapy. This protein, derived from advanced recombinant technology, showcases exceptional quality and efficacy in its ability to modulate immune responses.

The Recombinant Human CTLA4 Protein (FC Tag) is meticulously engineered to possess a fusion construct with an Fc tag, ensuring enhanced stability and prolonged half-life. This innovative feature allows for improved functionality and increased therapeutic potential, making it an invaluable asset in the development of novel immunotherapeutic strategies.

With its remarkable affinity for CD80 and CD86, the Recombinant Human CTLA4 Protein (FC Tag) acts as a potent antagonist, effectively inhibiting T-cell activation and promoting immune tolerance. This unique mechanism of action makes it an indispensable tool for researchers and clinicians alike, enabling precise manipulation of immune responses in various disease settings.

Furthermore, the Recombinant Human CTLA4 Protein (FC Tag) exhibits exceptional purity and bioactivity, guaranteeing reliable and reproducible results in a wide range of experimental applications. Its high-quality formulation ensures optimal performance, making it an ideal choice for both in vitro and in vivo studies.

In summary, the Recombinant Human CTLA4 Protein (FC Tag) represents a groundbreaking advancement in the field of immunotherapy. Its fusion construct with an Fc tag, remarkable affinity for CD80 and CD86, and exceptional purity and bioactivity make it an indispensable tool for researchers and clinicians seeking to unravel the complexities of immune regulation and develop innovative therapeutic interventions. Embrace the future of immunotherapy with the Recombinant Human CTLA4 Protein (FC Tag).